Alnylam Pharmaceuticals Inc

This innovative biotech stock has helped transform RNAi into an innovative new class of medicine. You have probably heard about RNA and mRNA innovation as the basis for the COVID-19 vaccine. This novel technology is set to shake up the medical world, and Alnylam is well-positioned to benefit from it.

$331.91
(as of Jul 3, 1:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Alnylam Pharmaceuticals Inc

Stock Price
$331.91
Ticker Symbol
ALNY
Exchange
NASDAQ

Industry Information for Alnylam Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Alnylam Pharmaceuticals Inc

Website
https://www.alnylam.com
Country
USA
Full Time Employees
2,230

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Fundamentals for Alnylam Pharmaceuticals Inc

Market Capitalization
$42,998,050,816
EBITDA
$-57,815,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
2,000
Earnings per Share
$-2.11
Earnings per Share Estimate Next Year
Profit Margin
-11.49%
Shares Outstanding
130,388,000
Percent Owned by Insiders
3.80%
Percent Owned by Institutions
97.50%
52-Week High
52-Week Low

Technical Indicators for Alnylam Pharmaceuticals Inc

50-Day Moving Average
200-Day Moving Average
RSI
69.79
ATR
8.87

Analyst Ratings for Alnylam Pharmaceuticals Inc

Strong Buy
12
Buy
12
Hold
7
Sell
1
Strong Sell
1

News About Alnylam Pharmaceuticals Inc

Jul 4, 2025, 1:38 PM EST
The United States market has experienced a 2.1% increase over the past week and is up 14% over the last year, with earnings projected to grow by 15% annually. See more.
Jul 4, 2025, 7:38 AM EST
Over the last 7 days, the United States market has risen by 2.1% and over the past 12 months, it is up by 14%, with earnings expected to grow by 15% per annum in the coming years. See more.
Jul 3, 2025, 1:38 PM EST
The U.S. stock market has recently experienced a surge, with the S&P 500 and Nasdaq Composite reaching new all-time highs following a robust June jobs report that exceeded expectations and fueled optimism in tech stocks. See more.
Jul 3, 2025, 10:47 AM EST
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $373.1 million dollar inflow -- that's a 8.2% increase week over week in outstanding units (from 53,775,000 to 58,175,000). See more.